Shijing Wang

Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models.

Min Wang, Yuqi Feng, H. Wen, 2020, American journal of cancer research.

The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.

Min Wang, R. Zhou, Renjie Li, 2017, Cancer letters.

Prediction of Anticancer Peptides with High Efficacy and Low Toxicity by Hybrid Model Based on 3D Structure of Peptides

Le Shen, Xinyu Yang, Min Wang, 2021, International journal of molecular sciences.

A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth

Zhuobin Xu, Xuelian Jia, Wenyi Wang, 2016, Scientific Reports.

MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.

Zhiguo Chen, Juan Zhang, Min Wang, 2016, Cancer letters.

The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.

Min Wang, R. Zhou, H. Wen, 2019, Experimental Cell Research.